Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.

Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, Martin T, Weng L, Park J, Fiala M, Faham M, Wolf J.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):131-139.e1. doi: 10.1016/j.clml.2013.09.013. Epub 2013 Oct 2.

PMID:
24629890
2.
3.

Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.

Rasmussen T, Poulsen TS, Honoré L, Johnsen HE.

Exp Hematol. 2000 Sep;28(9):1039-45.

PMID:
11008016
4.
5.

Immunoglobulin gene rearrangement in plasma cell dyscrasias: detection of small clonal cell populations in peripheral blood and bone marrow.

Fend F, Weyrer K, Drach J, Schwaiger A, Umlauft F, Grünewald K.

Leuk Lymphoma. 1993 Jun;10(3):223-9.

PMID:
8220121
6.

Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement.

Billadeau D, Prosper F, Verfaillie C, Weisdorf D, Van Ness B.

Leukemia. 1997 Sep;11(9):1565-70.

PMID:
9305613
8.

Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.

Vescio RA, Han EJ, Schiller GJ, Lee JC, Wu CH, Cao J, Shin J, Kim A, Lichtenstein AK, Berenson JR.

Bone Marrow Transplant. 1996 Jul;18(1):103-10.

PMID:
8832002
9.

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

Puig N, Sarasquete ME, Alcoceba M, Balanzategui A, Chillón MC, Sebastián E, Marín LA, Díaz MG, San Miguel JF, Sanz RG.

Ann Hematol. 2013 Jan;92(1):97-100. doi: 10.1007/s00277-012-1566-3. Epub 2012 Sep 7.

PMID:
22956183
11.

Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.

Fenk R, Ak M, Kobbe G, Steidl U, Arnold C, Korthals M, Hünerlitürkoglu A, Rohr UP, Kliszewski S, Bernhardt A, Haas R, Kronenwett R.

Haematologica. 2004 May;89(5):557-66.

12.
13.
14.

Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.

Korthals M, Sehnke N, Kronenwett R, Schroeder T, Strapatsas T, Kobbe G, Haas R, Fenk R.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1109-15. doi: 10.1016/j.bbmt.2013.04.025. Epub 2013 May 2.

15.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, Jiménez C, Sopena M, Moorhead M, Cedena T, Rapado I, Mateos MV, Rosiñol L, Oriol A, Blanchard MJ, Martínez R, Bladé J, San Miguel J, Faham M, García-Sanz R.

Blood. 2014 May 15;123(20):3073-9. doi: 10.1182/blood-2014-01-550020. Epub 2014 Mar 19.

16.

Tumour kinetics in multiple myeloma before, during, and after treatment.

Lincz LF, Crooks RL, Way SL, Granter N, Spencer A.

Leuk Lymphoma. 2001 Jan;40(3-4):373-84.

PMID:
11426560
17.

Circulating clonal lymphocytes in myeloma determined by mRNA in situ hybridization.

Joshua DE, Brown RD, Luo XF, Gibson J.

Blood. 1996 Aug 1;88(3):1125. No abstract available.

18.

Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.

Zhao X, Huang Q, Slovak M, Weiss L.

Am J Clin Pathol. 2006 Jun;125(6):895-904.

PMID:
16690489
19.

Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.

Takamatsu H, Ogawa Y, Kobayashi N, Obata K, Narisawa T, Nakayama K, Munemoto S, Aoki G, Ohata K, Kumano Y, Ozaki J, Murata R, Kondo Y, Terasaki Y, Kurokawa T, Miyamoto T, Shimizu N, Fukushima T, Yoshida A, Ueda T, Yoshida T, Nakao S.

Exp Hematol. 2013 Oct;41(10):894-902. doi: 10.1016/j.exphem.2013.05.004. Epub 2013 May 30.

PMID:
23727584
20.

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H, Fumero S, Jiménez C, Alcoceba M, Chillón MC, Sebastián E, Marín L, Montalbán MA, Mateos MV, Oriol A, Palomera L, de la Rubia J, Vidriales MB, Bladé J, Lahuerta JJ, González M, Miguel JF, García-Sanz R.

Leukemia. 2014 Feb;28(2):391-7. doi: 10.1038/leu.2013.217. Epub 2013 Jul 17.

PMID:
23860448

Supplemental Content

Support Center